9-(Tetrahydrofuran-2-yl)-9H-purine-6-amine
SQ 22,536
CAS: 17318-31-9
Molecular Formula: C9H11N5O
9-(Tetrahydrofuran-2-yl)-9H-purine-6-amine - Names and Identifiers
9-(Tetrahydrofuran-2-yl)-9H-purine-6-amine - Physico-chemical Properties
| Molecular Formula | C9H11N5O |
| Molar Mass | 205.22 |
| Density | 1.70±0.1 g/cm3(Predicted) |
| Melting Point | 160-161℃ |
| Boling Point | 474.8±55.0 °C(Predicted) |
| Solubility | H2O: 21mg/mL |
| Appearance | solid |
| Color | white to off-white |
| pKa | 3.82±0.10(Predicted) |
| Storage Condition | Keep in dark place,Inert atmosphere,2-8°C |
| In vitro study | SQ22536(250 µmol/L) attenuated the inhibitory effect of adenosine on ADP-induced platelet aggregation. It also attenuates the effect of adenosine on the elevation of cAMP levels in platelets. However, SQ22536 had no effect on the anti-platelet aggregation effect of inosine and ADP-induced platelet aggregation. |
| In vivo study | SQ22536 was able to inhibit the renal protective effect of liraglutide in KK/Ta-Akita mice. Treatment of KK/Ta-Akita mice with the combination of liraglutide and SQ22536 abolished the ameliorative effect of liraglutide on pathological damage to glomerular tissue. There was no increase in renal cAMP after SQ22536 treatment. Overall, the adenylate cyclase inhibitor SQ22536 inhibits the beneficial effects of liraglutide on the treatment of renal disease. |
9-(Tetrahydrofuran-2-yl)-9H-purine-6-amine - Risk and Safety
| Hazard Symbols | Xi - Irritant |
| Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
| Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
| WGK Germany | 3 |
9-(Tetrahydrofuran-2-yl)-9H-purine-6-amine - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 4.873 ml | 24.364 ml | 48.729 ml |
| 5 mM | 0.975 ml | 4.873 ml | 9.746 ml |
| 10 mM | 0.487 ml | 2.436 ml | 4.873 ml |
| 5 mM | 0.097 ml | 0.487 ml | 0.975 ml |
Last Update：2024-01-02 23:10:35
9-(Tetrahydrofuran-2-yl)-9H-purine-6-amine - Reference Information
| biological activity | SQ22536 (9-(tetrahydrofuran-2-yl)-9h-purin-6-amine) is an inhibitor of adenylate cyclase. PGE-1 inhibition of stimulated elevation of cAMP levels in intact human platelets. |
| Target | TargetValue Adenylyl cyclase |
| Target | Value |
| in vitro study | SQ22536(250 µmol/L) attenuates the inhibitory effect of adenosine on ADP-induced platelet aggregation. It also attenuates the effect of adenosine on the elevation of cAMP levels in platelets. However, SQ22536 had no effect on the anti-platelet aggregation effect of inosine and ADP-induced platelet aggregation. |
| in vivo study | SQ22536 inhibits the renal protective effect of liraglutide in KK/Ta-Akita mice. Treatment of KK/Ta-Akita mice with the combination of liraglutide and SQ22536 abolished the ameliorative effect of liraglutide on pathological damage to glomerular tissue. There was no increase in renal cAMP after SQ22536 treatment. Overall, the adenylate cyclase inhibitor SQ22536 inhibits the beneficial effects of liraglutide on the treatment of renal disease. |
Last Update：2024-04-09 21:11:58
Supplier List
Spot supply
Product Name: SQ 22,536 Visit Supplier Webpage Request for quotationCAS: 17318-31-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: SQ 22,536 Visit Supplier Webpage Request for quotationCAS: 17318-31-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History